Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours

J Endocrinol. 2006 Oct;191(1):249-61. doi: 10.1677/joe.1.06992.

Abstract

As for any solid tumour, pituitary adenoma expansion is dependent on neovascularization through angiogenesis. In this process, vascular endothelial growth factor (VEGF) and its receptors VEGFR-1, VEGFR-2 and neuropilin-1 (NRP-1) may play an outstanding role. The intention of this work was to study the expression/localization and possible function of VEGF receptors in pituitary adenomas. VEGF receptor mRNA and protein expression was studied by in situ hybridization, immunohistochemistry and RT-PCR in 6 normal human pituitaries, 39 human pituitary adenomas and 4 rodent pituitary adenoma cell lines. VEGFR-1 expressing somatotroph MtT-S cells were used as a model to study the role of VEGF on cell proliferation and to elucidate the underlying mechanism of action. In normal pituitaries, VEGFR-1 was detected in endocrine cells, whereas VEGFR-2 and NRP-1 were exclusively expressed in endothelial cells. In pituitary tumours, a heterogeneous VEGFR expression pattern was observed by IHC. VEGFR-1, VEGFR-2 and NRP-1 were detected in 24, 18 and 17 adenomas respectively. In the adenomas, VEGFR-1 was expressed in epithelial tumour cells and VEGFR-2/NRP-1 in vessel endothelial cells. Functional studies in VEGFR-1-positive MtT-S cells showed that the ligands of VEGFR-1 significantly stimulated cell proliferation. This effect was mediated through the phosphatidylinositol-3-kinase-signalling pathway and involves induction of cyclin D1 and Bcl-2. Based on our results, we speculate that the ligands of VEGF receptors, such as VEGF-A and placenta growth factor, not only play a role in angiogenesis in pituitary adenomas, but also affect the growth of pituitary tumour cells through VEGFR-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoma / chemistry*
  • Adenoma / metabolism
  • Adenoma / pathology
  • Adult
  • Aged
  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Blotting, Western / methods
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Chromones / pharmacology
  • Endothelial Cells / chemistry
  • Female
  • Humans
  • Immunohistochemistry / methods
  • In Situ Hybridization / methods
  • Ligands
  • Male
  • Middle Aged
  • Morpholines / pharmacology
  • Neuropilin-1 / genetics
  • Phosphoinositide-3 Kinase Inhibitors
  • Pituitary Gland / chemistry*
  • Pituitary Gland / metabolism
  • Pituitary Neoplasms / chemistry*
  • Pituitary Neoplasms / metabolism
  • Pituitary Neoplasms / pathology
  • Rats
  • Receptors, Vascular Endothelial Growth Factor / analysis*
  • Receptors, Vascular Endothelial Growth Factor / immunology
  • Receptors, Vascular Endothelial Growth Factor / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Somatotrophs / cytology
  • Somatotrophs / drug effects
  • Stimulation, Chemical
  • Vascular Endothelial Growth Factor A / analysis
  • Vascular Endothelial Growth Factor A / metabolism*
  • Vascular Endothelial Growth Factor A / pharmacology
  • Vascular Endothelial Growth Factor Receptor-1 / analysis
  • Vascular Endothelial Growth Factor Receptor-1 / genetics
  • Vascular Endothelial Growth Factor Receptor-2 / analysis
  • Vascular Endothelial Growth Factor Receptor-2 / genetics

Substances

  • Antibodies, Monoclonal
  • Chromones
  • Ligands
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Neuropilin-1
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Receptors, Vascular Endothelial Growth Factor
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor Receptor-2